Mehran Bahraini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mehran Bahraini has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Mahmood Shams
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
4 shared publications Akbar Dorgalaleh
Hamin Pazhuhan Tis Institute, Tehran, Iran
3 shared publicationsAlieh Fazeli
Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications- Akbar Dorgalaleh
Ali Asghar Clinical Research Development Centre (AACRDC), Department of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Ali Dabbagh
Department of Anesthesiology, School of Medicine, Anesthesiology Research Center, Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Alieh Fazeli
School of Paramedical Sciences, Shiraz University of Medical Sciences
1 shared publication
Latest Publications
- 29 June 2025
- Published by Springer Nature
- p. 165-172
Laboratory Diagnosis of Tissue Plasminogen Activator Deficiency
- 29 June 2025
- Published by Springer Nature
- p. 165-172
Laboratory Diagnosis of Tissue Plasminogen Activator Deficiency
- 29 June 2025
- Published by Springer Nature
- p. 187-230
Laboratory Diagnosis of Less CommonAcquired and Congenital Thrombophilic Risk Factors
- 29 June 2025
- Published by Springer Nature
- p. 187-230
Laboratory Diagnosis of Less CommonAcquired and Congenital Thrombophilic Risk Factors
- 29 June 2025
- Published by Springer Nature
- p. 95-110
Laboratory Diagnosis of Prothrombin G20210A Mutation
- 29 June 2025
- Published by Springer Nature
- p. 95-110
Laboratory Diagnosis of Prothrombin G20210A Mutation
- 29 June 2025
- Published by Springer Nature
- p. 67-74
Laboratory Diagnosis of Protein Z Deficiency
- 11 October 2023
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 50 (08) , e1
Erratum: Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden
The affiliations of Mehran Bahraini and Akbar Dorgalaleh have been updated in the above article published in the Seminars in Thrombosis & Hemostasis (DOI: 10.1055/s-0043-1770773). The correct affiliations appear as above. Article published online: 25 October 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 11 October 2023
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 50 (08) , e1
Erratum: Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden
The affiliations of Mehran Bahraini and Akbar Dorgalaleh have been updated in the above article published in the Seminars in Thrombosis & Hemostasis (DOI: 10.1055/s-0043-1770773). The correct affiliations appear as above. Article published online: 25 October 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 10 July 2023
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 50 (08) , 1067-1083
Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden
The factor V Leiden (FVL) polymorphism is known as the most common inherited risk factor for venous thrombosis. In turn, FVL is the leading cause of an activated protein C resistance (APCR) phenotype, in which the addition of exogenous activated protein C to plasma does not result in the expected anticoagulant effect. In the routine laboratory approach to the formal diagnosis of FVL, an initial positive screening plasma-based method for APCR is often performed, and only if needed, this is followed by a confirmatory DNA-based assay for FVL. Multiple methods with accepted sensitivity and specificity for determining an APCR/FVL phenotype are commonly categorized into two separate groups: (1) screening plasma-based assays, including qualitative functional clot-based assays, for APCR, and (2) confirmatory DNA-based molecular assays, entailing several tests and platforms, including polymerase chain reaction-based and non-PCR-based techniques, for FVL. This review will describe the methodological aspects of each laboratory test and prepare suggestions on the indication of APCR and FVL testing and method selection.
- 10 July 2023
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 50 (08) , 1067-1083
Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden
The factor V Leiden (FVL) polymorphism is known as the most common inherited risk factor for venous thrombosis. In turn, FVL is the leading cause of an activated protein C resistance (APCR) phenotype, in which the addition of exogenous activated protein C to plasma does not result in the expected anticoagulant effect. In the routine laboratory approach to the formal diagnosis of FVL, an initial positive screening plasma-based method for APCR is often performed, and only if needed, this is followed by a confirmatory DNA-based assay for FVL. Multiple methods with accepted sensitivity and specificity for determining an APCR/FVL phenotype are commonly categorized into two separate groups: (1) screening plasma-based assays, including qualitative functional clot-based assays, for APCR, and (2) confirmatory DNA-based molecular assays, entailing several tests and platforms, including polymerase chain reaction-based and non-PCR-based techniques, for FVL. This review will describe the methodological aspects of each laboratory test and prepare suggestions on the indication of APCR and FVL testing and method selection.
- 26 October 2021
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 48 (01) , 019-030
The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19
The cardinal pathology of coronavirus disease 2019 (COVID-19) is a primary infection of pulmonary tract cells by severe acute respiratory syndrome coronavirus 2, provoking a local inflammatory response, often accompanied by cytokine storm and acute respiratory distress syndrome, especially in patients with severe disease. Systemic propagation of the disease may associate with thrombotic events, including deep vein thrombosis, pulmonary embolism, and thrombotic microangiopathy, which are important causes of morbidity and mortality in patients with COVID-19. This narrative review describes current knowledge of the pathophysiological mechanisms of COVID-19-associated coagulopathy, with focus on prothrombotic changes in hemostatic mediators, including plasma levels of clotting factors, natural anticoagulants, components of fibrinolytic system, and platelets. It will also highlight the central role of endothelial cells in COVID-19-associated coagulopathy. This narrative review discusses also potential therapeutic strategies for managing thrombotic complications. Awareness by medical experts of contributors to the pathogenesis of thrombotic events in COVID-19 is imperative to develop therapeutics not limited to regular anticoagulants. Instituting cooperation among medical personnel and researchers may lessen this novel virus' impact now, and in the event of recurrence. Publication Date: 25 October 2021 (online) © 2021. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 26 October 2021
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 48 (01) , 019-030
The Impact of SARS-CoV-2 Infection on Blood Coagulation and Fibrinolytic Pathways: A Review of Prothrombotic Changes Caused by COVID-19
The cardinal pathology of coronavirus disease 2019 (COVID-19) is a primary infection of pulmonary tract cells by severe acute respiratory syndrome coronavirus 2, provoking a local inflammatory response, often accompanied by cytokine storm and acute respiratory distress syndrome, especially in patients with severe disease. Systemic propagation of the disease may associate with thrombotic events, including deep vein thrombosis, pulmonary embolism, and thrombotic microangiopathy, which are important causes of morbidity and mortality in patients with COVID-19. This narrative review describes current knowledge of the pathophysiological mechanisms of COVID-19-associated coagulopathy, with focus on prothrombotic changes in hemostatic mediators, including plasma levels of clotting factors, natural anticoagulants, components of fibrinolytic system, and platelets. It will also highlight the central role of endothelial cells in COVID-19-associated coagulopathy. This narrative review discusses also potential therapeutic strategies for managing thrombotic complications. Awareness by medical experts of contributors to the pathogenesis of thrombotic events in COVID-19 is imperative to develop therapeutics not limited to regular anticoagulants. Instituting cooperation among medical personnel and researchers may lessen this novel virus' impact now, and in the event of recurrence. Publication Date: 25 October 2021 (online) © 2021. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- Open Access
- 26 September 2020
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 43 (1) , 21-28
Standardization of Prothrombin Time/International Normalized Ratio (PT/INR)
The prothrombin time (PT) represents the most commonly used coagulation test in clinical laboratories. The PT is mathematically converted to the international normalized ratio (INR) for use in monitoring anticoagulant therapy with vitamin K antagonists such as warfarin in order to provide test results that are adjusted for thromboplastin and instrument used. The INR is created using two major PT ‘correction factors’, namely the mean normal PT (MNPT) and the international sensitivity index (ISI). Manufacturers of reagents and coagulometers have made some efforts to harmonizing INRs, for example, by tailoring reagents to specific coagulometers and provide associated ISI values. Thus, two types of ISIs may be generated, with one being a ‘general’ or ‘generic’ ISI and others being reagent/coagulometer‐specific ISI values. Although these play a crucial role in improving INR results between laboratories, these laboratories reported INR values are known to still differ, even when laboratories use the same thromboplastin reagent and coagulometer. Moreover, ISI values for a specific thromboplastin can vary among different models of coagulometers from a manufacturer using the same method for clot identification. All these factors can be sources of error for INR reporting, which in turn can significantly affect patient management. In this narrative review, we provide some guidance to appropriate ISI verification/validation, which may help decrease the variability in cross laboratory reporting of INRs.
- 26 September 2020
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 43 (1) , 21-28
Open AccessStandardization of Prothrombin Time/International Normalized Ratio (PT/INR)
The prothrombin time (PT) represents the most commonly used coagulation test in clinical laboratories. The PT is mathematically converted to the international normalized ratio (INR) for use in monitoring anticoagulant therapy with vitamin K antagonists such as warfarin in order to provide test results that are adjusted for thromboplastin and instrument used. The INR is created using two major PT ‘correction factors’, namely the mean normal PT (MNPT) and the international sensitivity index (ISI). Manufacturers of reagents and coagulometers have made some efforts to harmonizing INRs, for example, by tailoring reagents to specific coagulometers and provide associated ISI values. Thus, two types of ISIs may be generated, with one being a ‘general’ or ‘generic’ ISI and others being reagent/coagulometer‐specific ISI values. Although these play a crucial role in improving INR results between laboratories, these laboratories reported INR values are known to still differ, even when laboratories use the same thromboplastin reagent and coagulometer. Moreover, ISI values for a specific thromboplastin can vary among different models of coagulometers from a manufacturer using the same method for clot identification. All these factors can be sources of error for INR reporting, which in turn can significantly affect patient management. In this narrative review, we provide some guidance to appropriate ISI verification/validation, which may help decrease the variability in cross laboratory reporting of INRs.